On January 5, 2012 Neoprobe Corporation (NEOP) reported that it has completed its corporate name change to Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) (Press release, Navidea Biopharmaceuticals, JAN 5, 2012, View Source;p=irol-newsArticle&ID=1645017 [SID:1234510715]). The Company will begin trading under the ticker symbol, NAVB, on the NYSE Amex at market open today. The CUSIP number for NAVB common stock has also been changed to 63937X103.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Navidea name and logo represent the Company’s dedication to "NAVigating IDEAs" that translate cutting edge innovation and precision diagnostics technology into novel products to advance patient care.

Navidea’s website is expected to be launched in the coming days and may be found at www.navidea.com.